Home › NDC Lookup › RxCUI directory › RxCUI 1307633

Bosutinib 500 MG Oral Tablet — RxCUI 1307633

Name: Bosutinib 500 MG Oral Tablet (RxCUI 1307633)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic clinical drug

RxCUI 1307633 Semantic clinical drug · SCD ● Current RxNorm concept 9 FDA products 9 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1307633

Official nameBosutinib 500 MG Oral Tablet

Concept typeSemantic clinical drug (SCD)

RxNorm statusCurrent RxNorm concept

Also known asbosutinib 500 MG (as bosutinib monohydrate 516.98 MG) Oral Tablet

FDA products mapped9

Package NDCs mapped9

Reported Medicaid activity (SDUD)1,739 prescriptions · 20 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Bosutinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

You have a type of leukemia called Ph+ CML, which is driven by a faulty protein in your blood cells called BCR-ABL. Think of it like a stuck 'on' switch that keeps telling those ce...
What exactly is bosutinib treating in my body?
Yes — this is actually pretty important. Food significantly increases how much of the medicine your body absorbs, so taking it on an empty stomach means you'd be getting much less...
Do I have to take it with food every single time?

📖 Read our full Bosutinib guide →

🕸️ Concept Web — How Bosutinib 500 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Bosutinib 500 MG Oral Tablet RxCUI 1307633 Semantic clinical drug · SCD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Bosutinib 1307619 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Bosulif 1307625 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Bosutinib Oral Tablet 1307623 SCDF
- Bosutinib Oral Product 1307621 SCDG
- Bosutinib Pill 1307622 SCDG
- Bosutinib Oral Tablet [Bosulif] 1307627 SBDF
- Bosulif Oral Product 1307628 SBDG
- Bosulif Pill 1307629 SBDG
- Oral Tablet 317541 DF
- Oral Product 1151131 DFG
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Bosutinib 500 MG 1307632 SCDC
- Bosutinib 500 MG Oral Tablet [Bosulif] 1307635 SBD
- Bosutinib 500 MG [Bosulif] 1307634 SBDC

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Bosutinib 500 MG SCDC · 1307632
Bosutinib Oral Tablet SCDF · 1307623
Bosutinib Oral Product SCDG · 1307621
Bosutinib Pill SCDG · 1307622

Brand-Name Concepts

Bosutinib 500 MG Oral Tablet [Bosulif] SBD · 1307635
Bosutinib 500 MG [Bosulif] SBDC · 1307634
Bosutinib Oral Tablet [Bosulif] SBDF · 1307627
Bosulif Oral Product SBDG · 1307628
Bosulif Pill SBDG · 1307629
Bosulif BN · 1307625

📦 FDA Products & Package NDCs

9 products · 9 package NDCs

9 package NDCs map to RxCUI 1307633 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00069-0135-01	120 TABLET, FILM COATED in 1 BOTTLE (0069-0135-01)	BOSULIF	Pfizer Laboratories Div Pfizer Inc	2012-09-04
00069-0136-01	30 TABLET, FILM COATED in 1 BOTTLE (0069-0136-01)	BOSULIF	Pfizer Laboratories Div Pfizer Inc	2012-09-04
00069-0193-01	30 TABLET, FILM COATED in 1 BOTTLE (0069-0193-01)	BOSULIF	Pfizer Laboratories Div Pfizer Inc	2017-12-18
00069-0504-30	30 CAPSULE in 1 BOTTLE (0069-0504-30)	BOSULIF	Pfizer Laboratories Div Pfizer Inc	2024-01-02
00069-1014-15	150 CAPSULE in 1 BOTTLE (0069-1014-15)	BOSULIF	Pfizer Laboratories Div Pfizer Inc	2024-01-02
46708-0311-35	120 TABLET, FILM COATED in 1 BOTTLE (46708-311-35)	Bosutinib	Alembic Pharmaceuticals Limited	2026-05-19
46708-0312-30	30 TABLET, FILM COATED in 1 BOTTLE (46708-312-30)	Bosutinib	Alembic Pharmaceuticals Limited	2026-05-19
62332-0311-35	120 TABLET, FILM COATED in 1 BOTTLE (62332-311-35)	Bosutinib	Alembic Pharmaceuticals Inc.	2026-05-19
62332-0312-30	30 TABLET, FILM COATED in 1 BOTTLE (62332-312-30)	Bosutinib	Alembic Pharmaceuticals Inc.	2026-05-19

Observed labelers: Pfizer Laboratories Div Pfizer Inc (5) · Alembic Pharmaceuticals Inc. (2) · Alembic Pharmaceuticals Limited (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.